Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABY-029 imaging in head and neck cancer
NCT03282461Phase 1Completed
- Sponsor
- Dartmouth Health
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABY-029 in head and neck cancer (HNC), sponsored by Dartmouth Health. Primary endpoint: Signal detection (SNR >= 10). Started Jan 2018; status: completed.
02
Drugs
ABY-029
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03282461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282461.